Study on Relacorilant with Nab-Paclitaxel and Gemcitabine for Patients with Advanced Pancreatic Cancer

Inclusion Criteria

• Must sign a consent form before starting the study.
• Diagnosed with pancreatic cancer that has spread to other parts of the body.
• The cancer must have been diagnosed as metastatic within the last 6 weeks.
• Expected to live at least 3 more months.
• Must have at least one tumor that can be measured by scans.
• Must be in good general health, with a performance status of 0 or 1.
• Must be able to understand and agree to the study requirements.
• Must be able to swallow pills and not have severe nausea or vomiting.
• Must have good digestion and absorption.
• Must not have received any prior treatment for metastatic cancer.
• If previously treated for pancreatic cancer, it must have been more than 12 months ago, with no ongoing side effects.
• Must have good organ function.
• Women of childbearing potential must have a negative pregnancy test and agree to use birth control.

Exclusion Criteria

• Major surgery within the last 4 weeks.
• Previous treatments for metastatic cancer, including radiation, surgery, chemotherapy, or immunotherapy.
• Use of certain steroids recently.
• Previous treatment with gemcitabine or nab-paclitaxel for pancreatic cancer.
• Known genetic mutations related to breast cancer (BRCA).
• Severe nerve damage.
• Conditions requiring frequent steroid use.
• Severe allergies to study drugs.
• Use of certain medications that affect hormone receptors.
• Uncontrolled health conditions that could affect the study.
• Active infections like HIV, hepatitis B, or C.
• Untreated or uncontrolled brain cancer.
• History of other cancers within the last 3 years.
• Use of medications not allowed by the study.
• Participation in other cancer treatment studies.
• Recent vaccination with live vaccines.